Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17953926 | 0.82 | PDE4D (0.48) | PDE4APDE4DPDE4BPDE4CALDH1A1 | |
| SCHEMBL17035965 | 0.78 | LMNA (0.41) | PDE4APDE4DPDE4BPDE4CALDH1A1 | |
| SCHEMBL17035966 | 0.78 | HRH1 (0.49) | PDE4APDE4DPDE4BPDE4CALDH1A1 | |
| SCHEMBL3391000 | 0.76 | HRH1 (0.42) | ALDH1A1LMNASMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL17035964 | 0.74 | ALDH1A1 (0.46) | PDE4DALDH1A1LMNASMN1; SMN2MET | |
| SCHEMBL5492188 | 0.72 | CHRNB2 (0.44) | — | |
| SCHEMBL17035971 | 0.70 | MET (0.43) | ALDH1A1LMNASMN1; SMN2METNR3C1 | |
| SCHEMBL17035974 | 0.68 | LMNA (0.37) | PDE4APDE4DPDE4BPDE4CALDH1A1 | |
| SCHEMBL6981260 | 0.68 | LMNA (0.48) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9395993 | 0.67 | MTNR1A (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | PDE4A 1214/4885PDE4D 1122/4885PDE4B 986/4885 |
| US-20160213677-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | PDE4A 1214/4885PDE4D 1122/4885PDE4B 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.